0243 GMT - Breathing-tech provider ResMed doesn't get enough credit from the market for its operational cost control, UBS analyst Laura Sutcliffe reckons. Dual-listed ResMed is scheduled to report its December-quarter financials at the end of January and Sutcliffe thinks its core operating profit will come in about 2% ahead of the average analyst forecast. This is even though her revenue forecast is in line with average expectations. As for U.S. device sales, she tells clients in a note that app downloads suggest that its market share remains steady above 80%. UBS raises its target price on ResMed's U.S.-listed securities by 2% to US$255.00. The stock closed 0.2% lower at US$247.33. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
January 22, 2025 21:43 ET (02:43 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.